Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

Completed · Phase 3

Conditions studied: MDD

In brief

To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response in a school or work environment.

Key facts

Study ID
NCT02013609
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
People needed
48
Starts
2013-11-01
Expected to finish
2014-10-01
Last updated by the study team
2016-03-29

Who can join

Age: 18 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.